associated with type 2 diabetes and blood glucose levels [2] . Traditionally, melatonin is thought to be a 'dark hormone' as its expression is controlled by light from the retina to the pineal gland. In the elderly, melatonin can be used to treat insomnia and improve sleep quality [3] .
We tested whether rs10830963 associates with: (1) selfreported insomnia; or (2) short sleep. Finally, we studied whether sleep modifies the association of rs10830963 with blood glucose levels.
The association was examined in the Dietary, Lifestyle, and Genetic determinants of Obesity and Metabolic syndrome (DILGOM) study [4] , in which fasting blood glucose levels (10 h fasting, verified by interview), and self-reported insomnia and sleep duration were available. Blood glucose levels were measured from serum using the hexokinase method. Questionnaire-based sleep duration was assessed on the same day, and blood samples were taken, whereas insomnia was assessed with a questionnaire sent previously or, at the latest, the same day. RNA expression and genotyping were performed in 512 individuals from the Helsinki and Vantaa areas of southern Finland. The Health 2000 study (www.terveys2000.fi/doc/methodologyrep.pdf; accessed 1 December 2012) was used for replication.
The ethics committee of the Helsinki and Uusimaa Hospital District approved the study protocols. All participants provided written informed consent for the collection of samples and subsequent analysis.
Self-reported insomnia was queried in DILGOM with the question: 'Do you suffer from insomnia?' with answering options 'often', 'sometimes' and 'never'. Self-reported insomnia in Health 2000 was queried with the question: 'Have you had symptoms of insomnia or sleep disturbances during the past month?' with answering options ranging from 1 = not at all to 5 = very much. Insomnia phenotypes were dichotomised comparing the 'any insomnia symptoms' group to those Glucose levels were normalised using inverse-normal transformation of ranks. Individuals deviating 3 SD or more from the mean were removed. An additive model was used adjusting for age, sex and BMI, and in RNA expression with time of blood sample. The gene-environment interaction model Y = b0 + b1.ADD + b2.COV1 + b3.COV2 + b4.ADDx COV1 + b5.ADDxCOV2 + e was conducted using PLINK v1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/) [5] .
The association between rs10830963 and fasting blood glucose was confirmed at genome-wide significant level (Table 1) . Nominally significant associations were observed with sleep traits and with interaction of self-reported insomnia on rs10830963 association with blood glucose levels ( Table 1 ). The association with blood glucose levels was replicated in Health 2000, whereas association with sleep traits or interaction of rs10830963 and self-reported insomnia on glucose levels was not (Table 1) . No association between MTNR1B expression and rs10830963 was seen either in DILGOM (p = 0.31 β = 0.0068) or in the GTEx database (www.gtexportal.org/, accessed 1 November 2015).
The rs10830963 variant associated with glucose levels. Nominal association was seen with self-reported insomnia, and insomnia modified the genetic association of rs10830963 with glucose levels. However, the findings with insomnia were not replicated in Health 2000.
Notably, two earlier studies have evaluated the association of rs10830963 with sleep problems. Nominal associations of rs10830963 with insomnia and sleep maintenance and onset were reported [6] . Similarly, Tare et al showed a suggestive association with short sleep duration, although neither study saw interactions of short sleep or sleep problems on rs10830963 association with blood glucose levels or type 2 diabetes [6, 7] . These studies concluded that rs10830963 associates with glycaemic traits rather than sleep. Nevertheless, one challenge in the current and previous studies is that the sample sizes are underpowered to detect small effect interactions that would require 31,000 individuals to reach 80% power. Interestingly, another MTNR1B variant, rs10830964, was recently detected in a genome-wide association study on Both discovery and replication data sets are for CHR 11, rs10830963, minor allele G (frequency 0.36 in discovery data set)
DILGOM is partially (one third) overlapping with a previous study [9] Average (± SE) sleep duration was 7.30 ± 0.02 h, BMI 26.8 ± 0.07 kg/m 2 and fasting glucose 5.93 ± 0.01 mmol/l in the discovery data and 7.47 ± 0.03 h, BMI 27.3 ± 0.10 kg/m 2 and fasting glucose 5.36 ± 0.01 mmol/l in the replication data a p for interaction b p = 0.410, β = −0.040 when removing individuals using antidepressants or hypnotics during the previous month caffeine-induced sleep disturbance that excluded general insomnia [8] . We conclude that meta-analyses in existing data sets and deeper sleep phenotyping are required to reliably estimate the modifying effects of sleep on rs10830963 association with blood glucose levels and type 2 diabetes.
